GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Mosaic ImmunoEngineering Inc (OTCPK:CPMV) » Definitions » Forward Rate of Return (Yacktman) %

CPMV (Mosaic ImmunoEngineering) Forward Rate of Return (Yacktman) % : 0.00% (As of Mar. 2025)


View and export this data going back to . Start your Free Trial

What is Mosaic ImmunoEngineering Forward Rate of Return (Yacktman) %?

Yacktman defines forward rate of return as the normalized free cash flow yield plus real growth plus inflation. Mosaic ImmunoEngineering's forward rate of return for was 0.00%.

The historical rank and industry rank for Mosaic ImmunoEngineering's Forward Rate of Return (Yacktman) % or its related term are showing as below:

CPMV's Forward Rate of Return (Yacktman) % is not ranked *
in the Biotechnology industry.
Industry Median: 3.335
* Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.

Unlike the Earnings Yield %, the Forward Rate of Return uses the normalized Free Cash Flow of the past five years, and considers growth. The forward rate of return can be thought of as the return that investors buying the stock today can expect from it in the future.


Mosaic ImmunoEngineering Forward Rate of Return (Yacktman) % Historical Data

The historical data trend for Mosaic ImmunoEngineering's Forward Rate of Return (Yacktman) % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Mosaic ImmunoEngineering Forward Rate of Return (Yacktman) % Chart

Mosaic ImmunoEngineering Annual Data
Trend May15 May16 May17 May18 May19 May20 Dec21 Dec22 Dec23 Dec24
Forward Rate of Return (Yacktman) %
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Mosaic ImmunoEngineering Quarterly Data
May20 Aug20 Nov20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Forward Rate of Return (Yacktman) % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Mosaic ImmunoEngineering's Forward Rate of Return (Yacktman) %

For the Biotechnology subindustry, Mosaic ImmunoEngineering's Forward Rate of Return (Yacktman) %, along with its competitors' market caps and Forward Rate of Return (Yacktman) % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Mosaic ImmunoEngineering's Forward Rate of Return (Yacktman) % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Mosaic ImmunoEngineering's Forward Rate of Return (Yacktman) % distribution charts can be found below:

* The bar in red indicates where Mosaic ImmunoEngineering's Forward Rate of Return (Yacktman) % falls into.


;
;

Mosaic ImmunoEngineering Forward Rate of Return (Yacktman) % Calculation

Forward Rate of Return is a concept that Don Yacktman uses in his investment approach. Yacktman explained the forward rate of return concept in detail in his interview with GuruFocus. Yacktman defines forward rate of return as the normalized free cash flow yield plus real growth plus inflation. He said in the interview (March 2012, when the S&P 500 was at about 1400):

If the business is stable, this calculation is fairly straightforward. For instance, on the S&P 500 we would normalize earnings. We would then calculate what percentage of those earnings are not reinvested in the underlying businesses and are therefore free. Historically, for the S&P 500, this has been just under 50% of earnings. Currently, we expect the S&P to earn about 70 on a normalized basis, a number which is far below reported earnings due to our adjusting for record high profit margins. $70 X ½ / 1400 gives you a normalized free cash flow yield of approximately 2.5%.

The historical real growth rate of the S&P 500 (companies) is about 1.5%. Assuming an inflation rate of 2.5%, the forward rate of return on an investment in the S&P 500 is about 6.5% today (2.5% free cash flow yield plus 1.5% real growth plus 2.5% inflation).

Mosaic ImmunoEngineering's Forward Rate of Return of Mar. 2025 is

Forward Rate of Return=Normalized Free Cash Flow/Price+5-Year EBITDA Growth Rate
=0/0.7804+0
=0.00 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Mosaic ImmunoEngineering  (OTCPK:CPMV) Forward Rate of Return (Yacktman) % Explanation

Unlike the Earnings Yield, the Forward Rate of Return uses the normalized Free Cash Flow of the past five years, and considers growth. The forward rate of return can be thought of as the return that investors buying the stock today can expect from it in the future.

For the growth part of the Forward Rate of Return calculation, GuruFocus uses the 5-year average growth rate of EBITDA per share as the growth rate, and the growth rate is always capped at 20%. For the Free Cash Flow we use per share data averaged over five years. The reason we use five years is to make it comparable to the growth rate.


Be Aware

In the Forward Rate of Return calculation, the growth rate is added directly to today's free cash flow yield. Therefore the calculation is reliable only if the company can grow at the same rate in the future as it did in the past. Investors should pay close attention to this when researching growth stocks. A more accurate measurement for return is Return on Capital.


Mosaic ImmunoEngineering Forward Rate of Return (Yacktman) % Related Terms

Thank you for viewing the detailed overview of Mosaic ImmunoEngineering's Forward Rate of Return (Yacktman) % provided by GuruFocus.com. Please click on the following links to see related term pages.


Mosaic ImmunoEngineering Business Description

Traded in Other Exchanges
N/A
Address
9114 Adams Avenue, Suite 202, Huntington Beach, CA, USA, 92646
Mosaic ImmunoEngineering Inc is a development-stage biotechnology company focused on bridging immunology and engineering to develop novel immunotherapies to treat and prevent cancer and infectious diseases. It has a single operating segment for the purposes of assessing performance and making operating decisions.
Executives
Robert Baffi director C/O BIOMARIN PHARMACEUTICAL INC., 105 DIGITAL DRIVE, NOVATO CA 94949
Case Western Reserve University 10 percent owner 10900 EUCLID AVENUE, CLEVELAND OH 44106
Steven W King director, officer: President and CEO
Paul J Lytle director, officer: EVP, Chief Financial Officer
Robert L Garnick director C/O PATRIOT SCIENTIFIC, 2038 CORTE DEL NOGAL, SUITE 141, CARLSBAD CA 92011
Nicole Franziska Steinmetz director, officer: Chief Scientific Officer 871 WILBUR AVENUE, SAN DIEGO CA 92019
Dharmesh Mistry director 315 PEMBROKE COURT, SAN RAMON CA 94582
Carlton M Johnson director
Donald E Schrock director C/O INTEGRATED DEVICE TECHNOLOGY, INC., 6024 SILVER CREEK VALLEY ROAD, SAN JOSE CA 95138
Paul R Bibeau officer: VP, Business Development MICROSEMI CORP, 2381 MORSE AVE, IRVINE CA 92614
Frederick C Goerner officer: Chief Executive Officer MICROSEMI CORPORATION, ONE ENTERPRISE, ALISO VIEJO CA 92656
Clifford L Flowers officer: Chief Financial Officer C/O BAKBONE SOFTWARE, INC., 9540 TOWNE CENTRE DRIVE, SUITE 100, SAN DIEGO CA 92121
Harry L Tredennick director 6183 PASEO DEL NORTE #180, CARLSBAD CA 92011
Thomas J Sweeney officer: CFO
Helmut Jr Falk director

Mosaic ImmunoEngineering Headlines

From GuruFocus

Patriot Scientific Corporation Files Quarterly Report

By ACCESSWIRE AccessWire 04-12-2019

Patriot Scientific Corporation Files Quarterly Report

By ACCESSWIRE AccessWire 04-12-2019